Improvement in symptoms after H2-receptor antagonist-based therapy for eradication ofH pyloriinfection
| Autor: | Akimichi Imamura, Masahiro Asaka, Takeshi Hagiwara, Takumi Uchida, Manabu Nakagawa, Hiroshi Takeda, Tomonori Anbo, Soichi Nakagawa, Akira Fujinaga, Jyunji Yamamoto, Toshihiro Suga, Yuichi Shimizu, Mototsugu Kato |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Pyridines Lansoprazole macromolecular substances CYP2C19 Gastroenterology 2-Pyridinylmethylsulfinylbenzimidazoles Lafutidine Helicobacter Infections law.invention chemistry.chemical_compound Anti-Infective Agents Piperidines Randomized controlled trial law Clarithromycin Internal medicine Acetamides polycyclic compounds Humans Medicine Adverse effect Aged Helicobacter pylori business.industry Therapeutic effect Amoxicillin H Pylori General Medicine Middle Aged bacterial infections and mycoses Histamine H2 Antagonists chemistry Drug Therapy Combination Female business medicine.drug |
| Zdroj: | World Journal of Gastroenterology. 13:3836 |
| ISSN: | 1007-9327 |
| Popis: | AIM: To investigate the therapeutic effects of triple therapy combining lafutidine with clarithromycin and amoxicillin on H pylori infection and the resolution of gastroesophageal symptoms after eradication. METHODS: We conducted a randomized, multicenter, open-label controlled trial to compare the effectiveness of a triple therapy of lafutidine, clarithromycin, and amoxicillin (lafutidine group) with that of a triple therapy of lansoprazole, clarithromycin, and amoxicillin (lansoprazole group) in patients with H pylori infection. The study group comprised 22 patients with gastric ulcers and 18 patients with duodenal ulcers who had H pylori infection. RESULTS: H pylori eradication rates were similar in the lafutidine group (14/20, 70%) and the lansoprazole group (14/20, 70%). Gastroesophageal reflux and abdominal symptoms improved after eradication therapy in both groups, whereas abdominal discomfort, diarrhea, and constipation were unchanged. H pylori status had no apparent effect on improvement of gastroesophageal reflux or abdominal symptoms after treatment. Adverse events were similar in both groups. CONCLUSION: The triple therapy including lafutidine is equivalent to triple therapy including lansoprazole in terms of H pylori eradication rates and improvement in gastroesophageal reflux and abdominal symptoms. These results are attributed to the fact that lafutidine has strong, continuous antisecretory activity, unaffected by CYP2C19 polymorphisms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|